Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies.
Ontology highlight
ABSTRACT: More than a century after its first description, Langerhans cell histiocytosis (LCH) still remains an intriguing disease. Considerable progress in understanding its biology has been achieved recently. Description of the V600E BRAF mutation in samples of LCH tissue in 2010 was followed by description of additional mutations, all leading to constitutive ERK activation. Current experimental data suggest that LCH is a myeloid neoplasia with inflammatory properties, yet the exact pathophysiology remains poorly understood. Disease management paradigms have changed over time, closely reflecting the evolving view of the nature of the disease. The international Histiocyte Society have conducted three prospective clinical studies on multisystem LCH since the early 1990s. The standard frontlin
SUBMITTER: Hutter C
PROVIDER: S-EPMC5066850 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
ACCESS DATA